Education
About Us
Working with TipRanks
Follow Us
Organon (OGN)
NYSE:OGN
OGN Stock Chart & Stats
$8.76
-$0.16(-1.02%)
At close: 4:00 PM EST
$8.76
-$0.16(-1.02%)
Day’s Range― - ―
52-Week Range$6.18 - $17.23
Previous CloseN/A
Volume728.75K
Average Volume (3M)4.76M
Market Cap
$2.26B
Enterprise Value$10.94B
Total Cash (Recent Filing)$672.00M
Total Debt (Recent Filing)$8.83B
Price to Earnings (P/E)4.5
Beta0.40
Next Earnings
Feb 12, 2026EPS Estimate
0.76Next Dividend Ex-DateN/A
Dividend Yield4.8%
Share Statistics
EPS (TTM)1.01
Shares Outstanding259,982,900
10 Day Avg. Volume5,715,263
30 Day Avg. Volume4,758,893
Financial Highlights & Ratios
PEG Ratio-0.27
Price to Book (P/B)8.13
Price to Sales (P/S)0.60
P/FCF Ratio6.52
Enterprise Value/Market Cap4.84
Enterprise Value/Revenue1.74
Enterprise Value/Gross Profit3.15
Enterprise Value/Ebitda6.95
Forecast
1Y Price Target
$8.50Price Target Upside-2.97% Downside
Rating ConsensusStrong Sell
Number of Analyst Covering5
EPS Forecast (FY)3.96
Revenue Forecast (FY)$6.18B
Bulls Say, Bears Say
Bulls Say
Asset DivestitureDivestiture of the JADA System for $440 million plus potential milestone payments boosts cash resources and reduces exposure to non-core technology, increasing strategic flexibility for reinvestment or debt reduction.
Leverage TargetContinued aim to keep net debt to adjusted EBITDA below four times signals a focus on lowering leverage and could improve investor confidence in the company's balance sheet management.
Bears Say
Management TurnoverResignation of the CEO after an investigation into improper purchasing linked to a key product creates leadership uncertainty and could complicate execution of strategic plans.
Revenue Outlook And Shareholder ReturnsLowered revenue guidance driven by policy headwinds for a flagship product and respiratory business challenges, together with a prior unexpected dividend cut, heightens uncertainty about near-term earnings and cash returns.
Sales Practices InvestigationIdentification and cessation of improper sales practices, followed by personnel changes, raises material compliance concerns and could weigh on the stock until internal controls are proven effective.
Organon News
OGN FAQ
What was Organon’s price range in the past 12 months?
Organon lowest stock price was $6.18 and its highest was $17.23 in the past 12 months.
What is Organon’s market cap?
Organon’s market cap is $2.26B.
When is Organon’s upcoming earnings report date?
Organon’s upcoming earnings report date is Feb 12, 2026 which is in 25 days.
How were Organon’s earnings last quarter?
Organon released its earnings results on Nov 10, 2025. The company reported $1.01 earnings per share for the quarter, beating the consensus estimate of $0.936 by $0.074.
Is Organon overvalued?
According to Wall Street analysts Organon’s price is currently Overvalued.
Does Organon pay dividends?
Organon pays a Quarterly dividend of $0.02 which represents an annual dividend yield of 4.8%. See more information on Organon dividends here
What is Organon’s EPS estimate?
Organon’s EPS estimate is 0.76.
How many shares outstanding does Organon have?
Organon has 259,982,900 shares outstanding.
What happened to Organon’s price movement after its last earnings report?
Organon reported an EPS of $1.01 in its last earnings report, beating expectations of $0.936. Following the earnings report the stock price went up 13.726%.
Which hedge fund is a major shareholder of Organon?
Currently, no hedge funds are holding shares in OGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Organon Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Sell
Average Price Target:
$8.50 (-2.97% Downside)
$8.50 (-2.97% Downside)
Blogger Sentiment
Bullish
OGN Sentiment 87%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 190.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $501.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 0.8%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-44.46%
12-Months-Change
Fundamentals
Return on Equity
71.62%
Trailing 12-Months
Asset Growth
6.27%
Trailing 12-Months
Company Description
Organon
Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for various treatments to control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. In addition, the company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey.
OGN Company Deck
OGN Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture with strong operational metrics like adjusted EBITDA margin and free cash flow, alongside significant challenges in key segments like Nexplanon and respiratory, leading to a downward revenue guidance revision. The divestiture of Jada offers potential for financial improvement, but the impact of past sales practices remains a concern.View all OGN earnings summariesOGN Stock 12 Month Forecast
Average Price Target
$8.50
▼(-2.97% Downside)
Technical Analysis
Ownership Overview
0.37% Insiders
21.71% Mutual Funds
0.58% Other Institutional Investors
52.66% Public Companies and
Individual Investors